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Abstract
Background: Lower Urinary Tract Symptoms (LUTS) in men are a common clinical problem in urology and have
been historically strictly linked to benign prostatic hyperplasia (BPH), which may lead to bladder outlet obstruction
(BOO). New molecules have been approved and have entered the urologists’ armamentarium, targeting new
signaling pathways and tackling specific aspects of LUTS. Objective of this review is to summarize the evidence
regarding the new medical therapies currently available for male non-neurogenic LUTS, including superselective
α1-antagonists, PDE-5 inhibitors, anticholinergic drugs and intraprostatic onabotulinum toxin injections.
Methods: The National Library of Medicine Database was searched for relevant articles published between
January 2006 and December 2015, including the combination of “BPH”, “LUTS”, “medical” and “new”. Each article’s
title, abstract and text were reviewed for their appropriateness and their relevance. One hundred forty eight
articles were reviewed.
Results: Of the 148 articles reviewed, 92 were excluded. Silodosin may be considered a valid alternative to non-
selective α1-antagonists, especially in the older patients where blood pressure alterations may determine major
clinical problems and ejaculatory alterations may be not truly bothersome. Tadalafil 5 mg causes a significant
decrease of IPSS score with an amelioration of patients’ QoL, although with no significant increase in Qmax.
Antimuscarinic drugs are effective on storage symptoms but should be used with caution in patients with
elevated post-void residual. Intraprostatic injections of botulinum toxin are well-tolerated and effective, with a
low rate of adverse events; however profound ameliorations were seen also in the sham arms of RCTs evaluating
intraprostatic injections.
Conclusion: New drugs have been approved in the last years in the medical treatment of BPH-related LUTS.
Practicing urologists should be familair with their pharmacodynamics and pharmacokinetics.
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Background
Lower Urinary Tract Symptoms (LUTS) in men are
a common clinical problem in urology, and have
been historically strictly linked to benign prostatic
hyperplasia (BPH). These are classified into storage,
voiding and post micturition symptoms [1]. However,
BPH does not describe symptoms, but is instead a
histologic diagnosis, characterized by a micronodular
hyperplasia evolving into a macroscopic nodular en-
largement, which in turn may determine bladder
outlet obstruction (BOO). Although BOO as a con-
sequence of BPH may be responsible for a part of
male LUTS, studies have found that the prostate is
not the only actor in the complex play of male
LUTS. The bladder and it’s articulated neuronal con-
trol has been found to be another main character in
this plot [2]. To support this theory, also women
suffer from storage LUTS, with overactive bladder
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(OAB) being the most frequent cause. Moreover, al-
though voiding LUTS are the most common symp-
toms in BPH, storage are the most bothersome with
great impact on the patients’ quality of life (QoL)
[3]. As such, today it is insufficient and inappropri-
ate to consider the prostate as the only therapeutic
target in the management of LUTS in men, even
when BOO is present. Rather, the entire lower urin-
ary tract, from the afferent sensory nerves to the ur-
ethra, must be seen as a whole and in this direction
research is moving [4].
Historically, the standard medical treatment for LUTS
in men with BPH included α1-antagonists, 5α-reductase
inhibitors and phytotherapy. These agents remain indeed
today the mainstay of BPH treatment. Nonetheless, al-
beit full dose treatment, some patients remain symptom-
atic or may experience BPH progression, defined as the
onset of acute urinary retention (AUR), urinary infection
(UI) or the need of BPH-related surgery [5]. In addition,
the drugs routinely used in the management of LUTS
carry potential adverse effects (AE), which in turn may
be the cause of non-compliance of patients [6]. There-
fore, research is progressing in order to expand and
optimize medical strategies in the management of BPH-
related LUTS. Selective α1-antagonists, phosphodiester-
ase 5 (PDE5) inhibitors, and anticholinergics have been
tested and have entered our armamentarium for the
management of male LUTS. These agents, their pharma-
codynamics, pharmacokinetics and AEs should be well
known to the practicing urologist. Furthermore, our
knowledge of bladder and prostatic molecular anatomy
is constantly growing, and in parallel new biomolecular
targets are being identified and explored as new candi-
dates in BPH management. Objective of this systematic
review is to summarize the evidence regarding the new
medical therapies currently available for BPH-related
LUTS, and to give an overview on current research and
agents which may enter our everyday clinical practice in
the close future.
Methods
The National Library of Medicine Database was searched
for relevant articles published between January 2006 and
December 2015. A wide search was performed including
the combination of following words: “BPH”, “LUTS”,
“medical” “new”. Although recent articles were prioritized,
manuscripts with relevant historical findings were refer-
enced if necessary. Publications in English language were
preferred, though if necessary data was extrapolated even
from manuscripts in other languages. Evidence was not
limited to human data; results from animal and in vitro
experiments were also included in the review. Helsinki
declaration principles were respected and informed con-
sent was obtained. Each article’s title, abstract and text
were reviewed for their appropriateness and their rele-
vance. The initial list of selected papers was enriched by
individual suggestions of the authors of the present re-
view. Overall, 148 articles were reviewed. Of these, 92
were excluded after screening by the authors, leaving 56
articles eligible for the review (Fig. 1).
Results and Discussion
Selective α1-antagonists
α1-receptors are highly concentrated along the urinary
and ejaculatory tracts [7], and non-selective α1-
antagonists, alfuzosin, doxazosin, terazosin and tam-
sulosine are today the first line medical treatment in
men with moderate to severe symptoms of BPH [8].
There are three main subtypes of α1-receptors
expressed in the human organism: α1A, α1B and α1D-
receptors. These are all composed of seven trans-
membrane domains and are coupled with G proteins,
and their stimulation results in the activation of
phospholipase C with consequent increase in intra-
cellular Ca2+, which in turn stimulates contraction in
smooth muscular cells [7]. While α1B-receptors are
typically found in vascular tissue, where they mediate
arterial contraction, α1A and α1D are more specific
of the lower urinary tract [7]. Kojima et al. explored
the expression of these two subtypes in the transi-
tional zone of 28 prostatic tissue of men affected by
BPH, and found that 43 % were α1A dominant,
whereas 57 % α1Ddominant [9]. These receptors are
found also in the human detrusor muscle and in the
spinal cord, although the role of these localizations
in the pathology of LUTS remains controversial.
Moreover, in a rat model, α1-receptors stimulation
determined an increase in bladder vascular resistance,
with doxazosin determining an increase in bladder
blood flow [10].
Non-selective α1-antagonists act on the dynamic com-
ponent of BPH, counteracting smooth muscle contrac-
tion in the prostate, which is augmented in BPH, with a
consequent increase in urinary flow, reduction of LUTS
and improvement in QoL [11, 12]. A recent metanalysis
has demonstrated the reduction of bladder outlet ob-
struction index of −30.45 for silodosin, effect which was
higher than all other available α1-antagonists [13]. How-
ever, due to their concurrent action on α1B-receptors,
their use is associated with vascular AE, notably ortho-
static hypotension, headaches and dizziness [8].
Silodosin is the most recently developed, highly select-
ive antagonist of α1A-receptors. Its selectivity towards
α1A-receptor blockade was reported to be 38 times
higher than tamsulosin [13]. It has been shown that in
vitro silodosin possesses an elevated α1A/α1B binding ra-
tio of 162/1 [14], and in vivo experiments have demon-
strated its higher affinity for the urinary tract compared
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to the vascular system [15]. Kobayashi et al. demon-
strated that in dogs, while tamsulosin inhibits intraure-
thral pressure in a dose dependent manner with a
concurrent reduction of blood pressure (especially in old
dogs), silodosin determines similar effects on intraure-
thral pressures without altering blood pressure [16]. The
recommended dosage is 8 mg once –daily, which has
been found to be non-inferior to 4 mg twice-daily in a
double-blind randomized controlled trial (RCT) [17].
After administration, Silodosin is quickly absorbed and
has a bioavailability of 32 % at 8 mg/day (therapeutic
dose) [18]. Tmax is reached in 2.6 h and half life of the
drug is 13.3 h. The drug is then eliminated via fecal
(55 %) and renal (45 %) route [18].
On this pharmacologic basis, silodosin has been tested
in order to evaluate its non-inferior effect on BPH, while
minimizing peripheral vasodilatation and cardiovascular
effects which may be cause of falls and fractures, espe-
cially in the elderly [19]. Chapple et al. have explored the
efficacy of silodosin in a prospective, placebo controlled
trial [20]. Nine hundred ninety five European men were
randomized to receive either 8 mg silodosin, 0,4 mg
tamsulosin or placebo on a daily basis for 12 weeks. The
authors found a significant improvement of voiding and
storage LUTS after treatment with silodosin compared
to placebo (Δ IPSS: 2.3, 95%CI 1.4-3.2, p < 0.001)*, simi-
lar to that of tamsulosin, with a significant amelioration
of patients’ QoL. Furthermore, silodosin determined a
reduction of nycturia (Change from baseline silodosin vs
placebo: −0.9 vs-0.7, p = 0.013), effect which was non-
significant (p = 0.095) for tamsulosin vs placebo. Silodosin
also caused an increase in urinary flow of3.77 ml/s, though
this was not significantly higher compared to placebo (p =
0.089). Kawabe et al. reported results of a RCT which in-
cluded 457 Japanese men treated by silodosin, tamsulosin
or placebo, and found a significant decrease in total IPSS
in the silodosin arm compared to placebo [21]. Similarly,
Marks et al. found that 8 mg daily silodosin caused a sig-
nificant reduction of both storage and voiding LUTS
compared to placebo (Δ total 1.9, p < 0.0001; Δ storage
0.5, p = 0.0002; Δ voiding 1.4 p < 0.0001) [22]. Finally, it
appears that Silodosin may decrease nycturia, especially
in patients >65 years old in which desmopressin ther-
apy may be problematic: in a pooled analysis of three
RCTs, Eisenhardt et al. found that silodosin, compared
to placebo, determined a significant nicturia improve-
ment (53.4 vs. 42.8 %, p < 0.0001) [23], making it an in-
teresting drug in the elderly population.
Most studies reported that truly silodosin determines
less peripheral vascular AE compared to non-selective
α1-antagonists, as it does not determine significant ef-
fects on supine or orthotopic blood pressure [20, 24].
However, silodosin caused in most trials a higher rate of
anejaculation compared to non-selective α1-antagonists
or tamsulosin, with rates between 14.2 and 20.9 %: this
has been hypothesized to be a consequence of its select-
ivity for α1A-receptors, which are highly expressed along
the vas deferens, with a consequent reduction of their
Fig. 1 Flowchart of literature search
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contractility [20]. In 30 young sexually active patients,
Bozkurt et al. have found impaired ejaculation in 27/30
men, with significant enlargement of seminal vesicles
[24]. A long-term analysis following 104 men for 6 years
found a quite high discontinuation of silodosin (75 %),
mostly due to progression of disease and need for sur-
gery or to unknown causes; only 9/78 stopped treatment
due to side effects [25].
As such, silodosin may be considered a valid alterna-
tive to non-selective α1-antagonists, especially in the
older patients where blood pressure alterations may de-
termine major clinical problems and ejaculatory alter-
ations may be not truly bothersome.
Phosphodiesterase 5 Inhibitors
In addition to adrenergic fibers, key actors in micturition
are the nonadrenergic-noncholinergic fibers. This neural
system is implicated in the release and increase of nitric
oxide (NO), a cardinal molecule for intracellular signal-
ing which causes an increase of cyclic guanosine mono-
phosphate (cGMP), consequently catabolized by the
enzyme PDE. After its fundamental discovery in the
cavernous tissue and the development of PDE5 inhibi-
tors in the treatment of erectile dysfunction (ED), re-
searchers have demonstrated the presence of PDE-5
isoenzymes all along the lower urinary tract: they are in
fact expressed in the detrusor, the prostate, the urethra
and in pelvic vessels [26]. Here PDE-5 inhibition deter-
mines intracellular cGMP increase, which in turn may
promote micturition via different though yet unclear
mechanisms of action [27]. First, cGMP phosphorylates
and inactivates a protein kinase G (ρ-kinase) to pro-
mote smooth muscle cells relaxation [28]. In addition,
this ρ-kinase stimulates endothelin-1, which is a potent
vasoconstrictor which can mediate muscle contraction
[28]. Therefore, PDE-5 inhibition, via a cGMP increase,
reduces ρ-kinase activity and thus increases relaxation
in the lower urinary tract. Additionally, PDE inhibition
enhances smooth muscle cell relaxation increasing NO
activity as observed in the bladder neck, where nitrergic
innervation is prominent [26], in the prostate, were
PDE inhibition determines a dose-dependent tissue re-
laxation [29], and in urethral tissue [30]. Finally, PDE-5
inhibition leads to increased perfusion of pelvic organs
with the hypothesis that pelvic atherosclerosis with conse-
quent ischaemia may have a role in male LUTS [31], the
vasodilatation and increased end-organ perfusion deter-
mined by PDE-5 inhibitors on blood vessels may be bene-
ficial for LUTS. Of note, Bertolotto et al. demonstrated
increased prostatic perfusion on contrast-enhanced ultra-
sound after administration of tadalafil 20 mg [32]. More-
over, soluble cGMP plays a key role in the NO-mediated
inhibition of leukocyte rolling, and PDE5 inhibition may
reduce atherosclerotic damage and overall inflammation
by reducing leukocyte recruitment. Tadalafil was shown to
attenuate in vitro the expression of the inflammatory cyto-
kines TNF-α and IL-1βin pulmonary arteries [33] and of
TNF-α and IL-8 in endothelial cells [34]. Finally, cGMP
modulates afferent nerve fibers from the bladder and ur-
ethra, and PDE inhibitors may decrease the sensation of
bladder filling, thus reducing urgency [26, 35]. In this con-
text Minagawa et al. found that tadalafil significantly de-
creased afferent activity from the bladder in response to
bladder filling in a rat model [35] and Behr-Roussel et al.
reported a reduction of afferent signaling in rats with
spinal cord injury in response to bladder filling after treat-
ment with vardenafil [36].
Randomized, placebo-controlled clinical trials have
demonstrated that daily treatment with 5 mg tadalafil
improves safely BPH-related LUTS [37–39]. McVary et
al. found that tadalafil determined a decrease of total
IPSS of −3.8 compared to −1.7 with placebo after
12 weeks of treatment (p < 0.0001) [37]. QoL also signifi-
cantly improved (−0.7 vs −0.3, p = 0.008), while no sig-
nificant differences were observed for peak urinary flow
(Qmax). Roehrborn et al. confirmed these findings, and
noted in their trial that the dose of tadalafil with the best
risk-benefit profile was 5 mg, determining a reduction of
IPSS of −4.87 vs −2.27 with placebo (p < 0.001) [38].
Similarly, also QoL was significantly improved with tada-
lafil 5 mg. On post hoc analysis, the authors found that
although tadalafil caused a numerically superior increase
in Qmax compared to placebo, this increase was non-
significant [40]. Oelke et al. reported an amelioration of
total IPSS after 12 weeks of tadalafil 5 mg (Δ IPSS vs
placebo: −2.1, p = 0.001) and of QoL (−0.3, p = 0.022)
[39]. Moreover, these investigators described a signifi-
cant increase in Qmax: +2.4 ml/s (tadalafil) vs +1.2 ml/s
(placebo), p = 0.009: although this result is not consistent
with those previously reported [41], it must be kept in
mind that Qmax is intra individually variable and influ-
enced by age, sexual activity and baseline Qmax severity
[40]. In a meta-analysis, Gacci et al. synthesized that tada-
lafil determines a significant −2.85 decrease in overall IPSS
compared to placebo and a significant −1.85 decrease in
association with α1-inhibitors compared to α1-inhibitors
alone [42]. Clearly, tadalafil also significantly improves
erectile function with a net increase of the International
Index of Erectile Function. Indeed, a point of controversy
is whether the amelioration of IPSS and QoL, which are
subjective measurements, is a direct consequence of tada-
lafil’s pharmacologic effect on the lower urinary tract or if
the results observed are confounded by the fact that the
patients, having an improved potency, are more sexually
active and thus more satisfied. It appears however that the
amelioration seen in IPSS and QoL is observed both in
potent and impotent patients [43] and pooled data ana-
lyses determined that the LUTS amelioration was largely
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(92.5 %) determined by a direct effect of the drug [44].
Tadalafil is also being tested in combination therapy with
tamsulosin [45] or finasteride [46], demonstrating a more
pronounced amelioration of LUTS and ED symptoms in
the combination arms. Concerning AE, the vast majority
of manuscripts reported mild to moderate grade AE (dys-
pepsia and flushing), with a low rate (2–4 %) of discon-
tinuation of the therapy secondary to AE [42, 47].
In conclusion, tadalafil 5 mg is an effective and well
tolerated treatment for BPH-related LUTS, and is of car-
dinal importance when treating patients with concomi-
tant ED. Tadalafil causes a significant decrease of IPSS
score with an amelioration of patients’ QoL, although
with no significant increase in Qmax.
Great caution is advised when prescribing iPDE5. As
a consequence of systemic vasodilation, reduced venous
blood flow to the heart may trigger cardiac failure in
patients with preexisting cardiac insufficiency [42]. As
such, before prescribing iPDE5, the clinician must al-
ways exclude signs of cardiac insufficiency as dyspnea,
lower extremity oedema, chest pain. Moreover, for the
same pharmacologic reasons, concomitant treatment
with nitroderivates is an absolute contraindication to
iPDE5 utilisation [8].
Antimuscarinics
Two main subtypes of muscarinic receptor (MR) are
expressed in the lower urinary tract: M2 and M3 recep-
tors. Their proportions in detrusor membranes are re-
spectively evaluated at 71 % and 22 % [48]. While M3
are mainly responsible for detrusor contraction in both
healthy and pathologic conditions, M2 are predominant
in the urothelium and may be associated with pathologic
changes in the bladder [49]. It has been commonly and
reasonably thought that the main mechanism of action
of antimuscarinics in the treatment of LUTS is mediated
by a reduction of detrusor contractility. Specimens from
patients with bladder overactivity are consistently dener-
vated, and as such it has been hypothesized that possible
denervation supersensibility to acetylcholine may be cru-
cial in OAB physiopathology [50]. However MR are also
present in the urothelium and are here involved in
urothelial sensory function. The urothelium in fact re-
leases multiple signal molecules, including acetylcholine,
which activate unmyelinated afferent C-fibers present
in the suburothelial layer of the bladder wall, and this
release of acetylcholine is increased by bladder over-
stretching . This, associated to the denervation super-
sensitivity of the detrusor to acetylcholine, may induce
disorganized contraction of small muscular units in the
detrusor, generating pathologic afferent signals which
in turn may determine urgency symptoms [51].
Antimuscarinics have been prevalently used in female
patients with OAB: however today it is clear that in men
with BPH, storage symptoms are partially caused by the
bladder, with urodynamically proven OAB being a com-
mon cause [52]. As such antimuscarinic therapy has
emerged as a new option in male LUTS management
[8]. Chun-Hou Liao et al. have studied the predictors of
therapeutic success with a first line antimuscarinic treat-
ment in BPH men with predominant storage symptoms.
In their 197 patients group, receiving tolterodine in
monotherapy, higher baseline IPSS, higher baseline
Qmax and lower prostate volume were each associated
with a better response [53]. Treatment with antimuscari-
nics alone is still felt as dangerous in patients with BOO
by many urologists, due to the possible increased risk of
AUR. Abrams et al. reported that in men with mild to
moderate BOO, the antimuscarinic tolterodine 2 mg
twice daily for 12 weeks caused a significant increase in
post void residual (PVR) urine compared to placebo
(49 ml vs 16 ml): however, rates of AUR (3 %) and Qmax
were equal across both groups [54]. This is probably a
consequence of the action of antimuscarinics on the
storage phase of micturition and not on voiding, as there
is little evidence that these agents, at the therapeutic rec-
ommended doses, determine a significant reduction of
voiding contraction [55]. Nonetheless, in daily clinical
practice, the majority of patients is already under treat-
ment with an α1-antagonist, and present with persisting
storage symptoms. In this context, several trials have
explored the efficacy and safety of the addition of an
antimuscarinic to the α1-antagonist in these patients
[56–58]. The TIMES study included 879 men with
symptoms of BPH and OAB [56]. Patients were ran-
domized to receive either tolterodine 4 mg ER + tamsu-
loin, one of the two drugs alone or placebo. After
12 weeks, in the combination arm the patients reported
significant decrease in urgency incontinence episodes
(−0.88 vs −0.31, p = 0.005), frequency (−2.54 vs −1.41,
p < 0.001) and an amelioration of QoL. Although higher
than for placebo and for tamsulosin alone, the rate of
AUR was low for the combination (0.4 %) and the tol-
terodine arm alone (0.5 %). MacDiarmid et al. reported
significant amelioration of both storage and voiding
symptoms (p = 0.006) in men affected by BPH treated
with tamsulosin + oxybutinin 10 mg, with a non-
significant increase in PVR in treated patients com-
pared to placebo [57]. Similarly, in the VICTOR study,
398 men were randomized to receive tamsulosin plus
either solifenacin 5 mg or placebo. In the solifenacin
group, patients showed a significant reduction of urgency
episodes (−2.18 vs −1.10, p = 0.001) but a non-significant
reduction of frequency (−1.05 vs −0.67, p = 0.135) [58]. In
most trials the most frequent AE associated with antimus-
carinics is xerostomia [56, 57]. Increase in PVR urine,
though statistically significant in many studies, frequently
did not determine a significant increase in the risk of AUR
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requiring catheterization [56, 57]. However, as recom-
mended by current EAU guidelines, antimuscarinics are
therefore medications which can be prescribed in men
with BPH with residual storage symptoms after treatment
with α1-antagonists. Before to start a treatment with an
antimuscarinic, BPH patients should be monitored for
PVR and then closely followed [8]. Some authors have
been questioning the compliance to bi-therapy, con-
sidering the fact that the common chronic combin-
ation of antimuscarinics and αl-antagonists could be a
burden for the patients. Barkin et al. reported a retro-
spective analysis based on patients prescriptions reim-
bursement data. They concluded that patients treated
in combination therapy showed an improved persist-
ence over a year period, compared to those on αl-
antagonists monotherapy [59].
Concerning anticholinergic drugs, great care is neces-
sary when prescribing these drugs in the elderly, as cog-
nitive deterioration may be a serious consequence and
one must bear in mind that 16 % of patients >70 years
show some form of cognitive impairment [60]. Indeed,
encephalic cholinergic activity, and in particular M1 and
M2 receptors which represent over 60 % of the brains
cholinergic receptors, are vital in cognitive function [61].
The only antimuscarinic which was accorded a benefi-
cial safety profile in the elderly is Fesoterodine, as this
drug was studied specifically in the ageing population
[62–64]. In the SOFIA trial 581 patients >65, of which
33 % were >75 years old and frequently on polyphar-
macy, completed a 3 month double-blind randomized
trial of Fesoterodine versus placebo [62]. At 12 weeks,
patients in the treatment arm demonstrated reduced ur-
gency (−3.8 episodes), pollakiuria and nycturia (−0.55 epi-
sodes) (all p < 0.001) compared to placeebo. Fesoterodine
determined a similar rate of adverse events compared to
placebo (39.8 % vs 36.1 %), mostly mild xerostomia. Of
note, no clinically relevant changes in cognitive function
(evaluated through the mini-mental status examination)
were observed throughout the study in both arms. This
may be attributed to the high affinity of Fesoterodine for
the M3 receptor and its inability to pass the blood–brain
barrier [65]. In any case, great care is advised with anti-
cholinergic drugs and a high level of suspiciousness in
case of cognitive deterioration while receiving treatment.
Intraprostatic agents
In addition to classic oral therapy, medical agents may
be injected directly in the prostate [66]. This is a
promising minimally invasive approach in patients who
are unresponsive to medical treatment, who experience
debilitating AE or who are poor candidates for surgery.
The rationale for this therapy is the ability of some
agents to determine prostatic involution and promote
apoptosis, thus shrinking prostatic volume and
ameliorating LUTS [66]. In addition, these agents may
modulate prostatic afferent nerves, reducing nocicep-
tion and improving BPH-related symptoms. However,
it must be remembered that profound ameliorations
were seen also in the sham arms of RCTs evaluating
intraprostatic injections [67]: as such, the results of
such trials must always be redimensioned and relativ-
ized to the sham-control arm, rather than considering
the absolute results.
Ethanol has been explored as agent for intraprostatic
administration, with favorable results. Investigators
found a significant reduction of IPSS and an amelior-
ation of Qmax and QoL [68, 69]. However results are sel-
dom durable, and patients frequently require re-
treatment, which has been reported necessary in over
40 % of patients [70]. Intraprostatic botulinum toxin in-
jection is a very promising and is being throughout fully
explored. This neurotoxin exists in seven different sub-
types, and the most widely used has been Onabotulinum
toxin A. Though yet unclear, it has been hypothesized
that this may enhance prostatic apoptosis, down-
regulate α-receptors and modulate afferent signaling in
the prostate [71]. Investigators have reported positive
and significant improvement of LUTS in men with BPH
treated by Onabotulinum toxin injection [72]. Generally,
doses between 100U and 300U have been used during
most trials but Arnouk et al. reported similar functional
and safety results after injection of 100U and 200U [73].
To date the largest trial testing botulinum in BPH was
recently published by Marberger et al. in a phase II
placebo-controlled trial, enrolling 380 men [74]. Patients
were randomized to receive 100U, 200U or 300U Ona-
botulinum toxin A or 0.9 % saline, and were followed for
72 weeks. The investigators found a meaningful im-
provement of BPH parameters after botulinum injection,
including IPSS (Δ IPSS: 5.6 to 6.6, according to dose),
Qmax(Δ = 2.0 to 2.4 ml/s, according to dose) and QoL.
However, a pronounced placebo effect was observed,
with patients in the control arm experiencing a similar
symptom amelioration, yielding non-significant differ-
ences in outcomes across the treatment and control
arm. Overall, intraprostatic injections of botulinum
toxin are well-tolerated, with a low rate of AE mainly
associated with the administration of the drug (2 %
prostatitis) [74] and not the compound itself. Moreover,
no sexual AEs are reported, with full conservation of
sexual potency [75].
Future perspectives in the medical treatment of BPH
Research in the field of BPH therapy is continuously
progressing. As our molecular understanding of blad-
der, prostatic, urethral anatomy and pathophysiology
advances, so do the experimental studies and clinical
trials exploring new drugs in this domain. In particular
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there is growing interest in the role of inflammation,
the vitamin D receptor signaling pathway and the activ-
ity of β3-receptors in BPH-mediated LUTS.
Inflammation has been associated with BPH pathogen-
esis and progression, with multiple cytokines and inflam-
matory cells responsible for the increased risk of BPH
determined by prostatic inflammation [76]. The COX
pathway leads to the production of free radicals and
consequent oxidative stress: as such, a possible thera-
peutic effect of non-steroidal anti-inflammatory drugs
has been hypothesized [77, 78]. Di Silverio et al. found
that the combination of finasteride and a COX-2 inhibi-
tor, rofecoxib 25 mg/die, caused a significant improve-
ment in IPSS score (p = 0.0001) and of Qmax (p = 0.03)
compared to finasteride alone [77]. Moreover flavocoxid,
an inhibitor of COX and 5-lipoxygenase enzymes, re-
duced prostate weight, increased the expression of Bax
and caspase-9 mRNA (pro-apoptotic) and decreased that
of Bcl-2 (anti-apoptotic) in mice with induced BPH [78].
Although COX inhibitors could have a future role in the
management of BPH, clinical evidence is still lacking and
their application in BPH must be considered experimental.
The vitamin D receptor (VDR) signaling pathway could
be associated with BPH and LUTS [79, 80]. Investigators
have found that VDR agonists, notably elocalcitol, a syn-
thetic derivative of vitamin D3 that regulates cell prolifera-
tion and apoptosis may inhibit the androgen-dependent
and androgen-independentprostatic cell proliferation [81].
It can also reduce IL-8 secretion by inflammatory cells
in the prostate by targeting the NF-kB pathway [80].
Elocalcitol modulates bladder contractility by inhibit-
ing the calcium-sensitizing RhoA/ROCK with a poten-
tial interest in storage symptoms control [82]. In a
phase II RCT, Colli et al. treated 57 men with prostate
volumes ≥40 ml with elocalcitol for 12 weeks, finding a
significant reduction of prostate growth compared to
placebo (−2.90 vs +4.32, p < 0.0001) [79]. However
until now in humans, elocalcitol was demonstrated
with a very good safety profile but only exhibited lim-
ited efficacy on LUTS in patients with BPH and overactive
bladder. Recent data in animals reported the interest of
association of elicalcitol with tolterodine [83]. Clinical ex-
perimentation is continuing to evaluate its potential role
in LUTS due to BPH and OAB management.
In the bladder the predominant form of β-adrenoceptor
is the β3-receptor subtype. Its activation is associated with
increased bladder capacity without change in micturition
pressure, residual volume, or voiding contraction [84].
Mirabegron is a β3-receptor agonist that has been suc-
cessfully tested in male and female patients suffering from
OAB without BOO [85, 86] and is now being evaluated
also in men with associated BOO. Nitti et al. in a random-
ized, double-blind, phase II study, treated 200 men af-
fected by BOO with mirabegron 50, 100 mg or placebo.
Mirabegron 50 mg was effective in reducing urgency and
frequency, without impairing Qmax and with a non-
significant increase in PVR urine [87]. Otsuki et al. studied
the response to mirabegron 50 mg in two groups of
patient, newly diagnosed OAB and BPH related OAB
unresponsive to antimuscarinics [88]. They showed a
significant improvement of OAB Symptom Score and
IPSS –QOL index, voiding symptoms with no signifi-
cant difference on post-void residual, supporting the
use of Mirabegron in second line after failure of anti-
muscarinics. A recent randomized controlled trial
tested the add-on of Mirabegron 50 mg to 0.2 mg tam-
sulosine compared to tamsulosine alone, with a signifi-
cant benefit on urgency, daytime frequency and quality
of life index after 2 months of therapy [89]. Although
the increase in post-void residual urine volume was
significantly greater in the add-on group, AUR was ob-
served only in one man. The results of these trials sug-
gest that Mirabegron may be effective in reducing
storage LUTS and safe in patients affected by BOO.
Ion channel transient receptor potential subtype mela-
statin 8 (TRPM8) is an important factor in the mechan-
ism of detection of bladder filling, whose activation can
activate the initiation of micturition. Ito et al. described
their activity in a rat model, finding [90] that administra-
tion of the TRPM8 antagonist RQ-00203078 significantly
increased bladder capacity and voided volume. More-
over, the activation of TRPM8 is enhanced by cold tem-
peratures, as found by Uvin et al. [91], demonstrating
the known empirical finding that cold temperatures
worsen urgency. Although these findings represent im-
portant steps in the understanding of the physiology of
micturition, their clinical relevance to date remains
limited: TRPM8 antagonists (PF-05105679) have been
tested in phase 1 trials, however given the generalized
expression of these receptors, significant side effects
were recorded including hypothermia [92], thus limiting
their possible clinical application.
PRX302 is a PSA-activated bacterial protoxin which
has the ability to bind to cellular membranes, where it
creates transmembrane channels with consequent lytic
cell death. After intriguing results in animal models
where intraprostatic injection of PRX302 caused ex-
tensive, organ-confined prostatic shrinkage [93], this
molecule has been tested in humans with favorable
preliminary results. In a phase II trial, 18 men received
intraprostatic injections of PRX302 [94]. After one
year there was an average change from baseline IPPS
of −9.7 and of +2.8 ml/s inQmax. Moreover, 12/18
(67 %) patients showed a ≥20 % reduction inprostate
volume at day 90. Of note, no patient experienced sexual
AEs. Clearly, though these results appear very encour-
aging, the small sample size limits their interpretation and
PRX302 is still considered experimental.
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NX-1207 is another protein for intraprostatic injection
currently under evaluation in preliminary studies. This
molecule promotes focal apoptosis, with significant re-
ductions of prostate volumes in animal models [95]. Hu-
man phase II studies found that intraprostatic injection
of NX-1207 determined a reduction of AUA Symptom
Score, maintained during 6 months follow-up, with no
significant AE [95]. Two phase III trials are underway
and their results are awaited to better analyze the true
potential of this drug in BPH management.
Conclusions
Today, BPH should not be considered a strictly prostatic
disease, as it has been demonstrated that the entire
lower urinary tract is involved in a complex pathophysi-
ology. New medical treatments are available and the
right drugs should be prescribed t the correct patients.
Silodosin has similar efficacy compared to tamsulosin,
with a lower risk of cardiovascular AE, making it a
good choice for older patients requiring α1-antagonists.
Tadalafil improves BPH symptoms in men with and
without ED, and could be considered especially when
ED and BPH coexist. Antimuscarinics are effective on
residual storage symptoms after α1-antagonist therapy
and appears to be safe even in men with moderate
BOO, though these patients should be strictly moni-
tored with regular PVR measurements. Intraprostatic
injections of onabotulinum toxin A are a promising
minimally invasive option for LUTS management, al-
though their true efficacy is still object of evaluation.
Finally, research in the field of BPH medical treatment
is actively progressing, with new agents as elocalcitol
and mirabegron being tested. Future basic research and
prospective clinical trials must continue in order to in-
crease our pharmacologic armamentarium for men suf-
fering from LUTS, in order to reduce BPH progression,
improve QoL and decrease AEs.
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